Ipstyl (Lanreotide)

Lanreotide mimics natural somatostatin and binds to somatostatin receptors on target cells, especially SSTR2 and SSTR5. This binding blocks adenylate cyclase activity, reduces cyclic AMP, and suppresses the release of several hormones and growth factors that drive disease activity.

The prescribed dose of Ipstyl is determined by the treating physician based on the individual’s condition, disease severity, and response to therapy. Dosing regimens are personalized and should follow the prescriber’s instructions.

Safety data for lanreotide in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To order Ipstyl, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required) and import documentation.

The primary alternative is octreotide, another somatostatin analogue. Both agents suppress hormone secretion, but lanreotide has a longer dosing interval and may be administered less frequently, which can improve patient convenience. Efficacy and safety profiles are broadly comparable, though individual response varies.

Ipstyl should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Keep the product in its original packaging until use to maintain stability.

Ipstyl is given by subcutaneous injection, typically performed by a healthcare professional. The injection site is rotated to minimise local irritation, and the product is administered according to the prescriber’s schedule.

Serious risks include gallbladder disease such as gallstones or cholecystitis, pancreatitis, severe hyperglycaemia, allergic reactions including anaphylaxis, and rare cardiac arrhythmias. Patients should be monitored for these events and advised to seek immediate medical attention if they occur.

Ipstyl is contraindicated in patients with known hypersensitivity to lanreotide or any of its excipients. Caution is advised for individuals with severe uncontrolled diabetes, active gallbladder disease, or those who are pregnant or breastfeeding without a clear clinical justification.